Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077511 | 0.81 | VCAM1 (0.46) | CYP1A2TSHRALDH1A1CYP3A4GPR35 | |
| SCHEMBL6508786 | 0.81 | ALDH1A1 (0.40) | CYP1A2ALDH1A1CYP3A4MAPTKDM4E | |
| SCHEMBL540381 | 0.81 | MAPT (0.45) | CYP1A2TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL1338960 | 0.78 | VCAM1 (0.44) | CYP1A2TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL29546613 | 0.78 | VCAM1 (0.44) | CYP1A2TSHRALDH1A1CYP3A4MAPT | |
| SCHEMBL29671003 | 0.78 | TSHR (0.42) | CYP1A2TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL624089 | 0.78 | TSHR (0.42) | CYP1A2TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL4893554 | 0.78 | TSHR (0.50) | CYP1A2TSHRALDH1A1CYP3A4RECQL | |
| SCHEMBL19616214 | 0.77 | ALDH1A1 (0.43) | CYP1A2ALDH1A1CYP3A4MAPTHSD17B10 | |
| SCHEMBL1338313 | 0.77 | HCAR3 (0.43) | CYP1A2ALDH1A1RECQLMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2023-12-21 | — | — | US | disclosed |
| CN-116139138-A | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | SAGIMET BIOSCIENCES INC. (US) | 2023-04-11 | — | — | US | disclosed |
| CN-110177551-B | Heterocyclic modulators of lipid synthesis | 3-V生物科学股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-10-27 | — | — | US | disclosed |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-09-22 | — | — | US | disclosed |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | Saginiet Biosciences Inc. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3190108-B1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20030225063-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225062-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635633-B2 | Substituted pyrazoles | ORTHO-PHARMACEUTICAL, INC. | 2003-10-21 | — | — | US | disclosed |
| US-6579896-B2 | Immunology response; autoimmune disease | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-17 | — | — | US | disclosed |
| EP-1315492-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309592-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020040019-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020013-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014317-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225062-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CYP1A2 1392/4885TSHR 2617/4885ALDH1A1 2313/4885 |
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CYP1A2 293/4885TSHR 3670/4885ALDH1A1 651/4885 |
| US-20020040019-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CYP1A2 1392/4885TSHR 2617/4885ALDH1A1 2313/4885 |
| US-20230405016-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CYP1A2 467/4885TSHR 3688/4885ALDH1A1 768/4885 |
| US-20030225063-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | CYP1A2 1392/4885TSHR 2617/4885ALDH1A1 2313/4885 |
| US-20240400552-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | CYP1A2 293/4885TSHR 3670/4885ALDH1A1 651/4885 |
| US-11034690-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | CYP1A2 421/4885TSHR 3590/4885ALDH1A1 724/4885 |
| US-20220296605-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, SCD | CYP1A2 421/4885TSHR 3590/4885ALDH1A1 724/4885 |
| US-12551490-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, FADS2 | CYP1A2 181/4885TSHR 1369/4885ALDH1A1 540/4885 |
| US-20020147189-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | CYP1A2 72/4885TSHR 3090/4885ALDH1A1 939/4885 |
| US-11622968-B2 | Heterocyclic modulators of lipid synthesis | FASN, FADS1, SCD | CYP1A2 421/4885TSHR 3590/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.